ContraFect Corporation announced that Steven C. Gilman, Ph.D., the Company's Chief Executive Officer and Chairman of the Board, will be on medical leave from his CEO position as of March 16, 2017. Dr. Gilman will continue to serve as Chairman during his temporary leave of absence. He is expected to return to his CEO role in the third quarter of 2017. The Company's Board has established an Interim Office of the Chief Executive Officer for the duration of Dr. Gilman's absence as CEO, consisting of the following executive officers of the Company: Cara Cassino, M.D., Executive Vice President of Research and Development and Chief Medical Officer; Natalie Bogdanos, General Counsel and Corporate Secretary; Michael Messinger, Senior Vice President, Finance; and Josh Muntner, Senior Vice President, Business Development, who will collectively assume the CEO duties on an interim basis, effective March 16, 2017. The Interim Office of the CEO will report directly to a newly formed subcommittee of the Board, designated the CEO Oversight Committee, consisting of directors Sol Barer, Ph.D., Dr. Gilman, Michael Otto, Ph.D. and Lisa Ricciardi.